Pfizer Recalls More Quinapril Due to Potential Carcinogen

The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.
Medscape Medical News
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.
Medscape Medical News